Asuragen Incorporated
Austin, TX Part of Bio-Techne Corporation
- UEI
- E8M9NXN4X4Y7
- CAGE
- 4GGP6
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
RDJKATCM39L5
-
Parent
RDJKATCM39L5
- SAM.gov registration date
- Physical address
- 2150 Woodward St #100, Austin, TX 78744, USA
- Website
- asuragen.com
- Founded
- 2006
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $77,360 |
| FY2025 | $169,115 |
| FY2024 | $180,888 |
| FY2023 | $200,205 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $77,360 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Asuragen, Inc. is a molecular diagnostics company that provides genetics and oncology testing kits to streamline workflows for clinical research and laboratories. Through prime federal contract awards, Asuragen has provided reagents, kits, and testing materials compatible with specialized medical equipment used for cancer and leukemia testing at Army medical facilities and VA health networks. These awards have been primarily purchase orders and definitive contracts with no set-aside designations, stemming from the Department of Defense, Veterans Affairs, and Health and Human Services.
Asuragen's federal contract awards have delivered Quantidex PCR reagents, Armored RNA, and BCR ABL reagents used specifically with Applied Biosystems instrumentation and compatible with unique testing procedures at government medical centers. Performance periods for these awards range between 2019-2027, with obligations between $15,000 to over $800,000 to supply quantities of Asuragen's proprietary reagents and kits meeting specialized compatibility and FDA approval requirements. No subcontractors are noted on the available prime contract award details.
Through NIH and NICHD grants, Asuragen has also conducted research to develop multiplexed tests for spinal muscular atrophy, carrier screening for hemoglobinopathies, and prenatal testing methods using microfluidic technology. Additional grants have funded projects applying deep learning and AI tools for enhancing molecular diagnostics, as well as developing unified workflows to screen for inherited ataxias. These grants provided between $180,000 to $220,000 in assistance, with performance periods ranging from 2019-2021. No subrecipients are noted on the available prime grant award details.
Quick answers
Is Asuragen Incorporated registered in SAM.gov?
Yes. Asuragen Incorporated's SAM.gov registration is active through January 7, 2027.
How much has Asuragen Incorporated received in federal contracts?
Federal contracts obligated $169,115 to Asuragen Incorporated in fiscal year 2025 and $627,568 in fiscal years 2023 through 2027.
How does Asuragen Incorporated rank among federal contractors?
Asuragen Incorporated ranked #85 in NAICS 325413 in FY2025.
What is Asuragen Incorporated's most recent federal award?
Asuragen Incorporated's most recent federal contract award is Armored RNA (75D30123P15844), from CDC Pittsburgh, on December 5, 2022.
On GovTribe
See Asuragen Incorporated's full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors